VC-backed ReViral taps Musso as CFO
ReViral Ltd, a developer of novel, antiviral compounds that target respiratory syncytial virus, has named Alan A. Musso as chief financial officer. Prior to joining ReViral, Musso worked at Peloton Therapeutics Inc. ReViral's backers include New Leaf Venture Partners, Novo Ventures, Perceptive Advisors, Andera Partners, OrbiMed and Brace Pharma Capital.
21 October 2019•4 mins read
